Market Cap
$14.4B
NBIX
NEUROCRINE BIOSCIENCES INC
$143.18 ▲ +1.76%
Prev close $140.71Market cap$14.4B
ConsensusStrong Buy
12-mo target$207.81 (+45.1%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)41 New Institutional Positions9 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on NBIX right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (86%)
Inst. Holders
50 funds
Inst. Value
$12.7B
Inst. Activity
41 buys / 9 sells
Insider Activity
$0.00 buy / $9.2M sell
Insider Net $
-$9.2M
SEC Reports
17
Price chart 30d -9.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Sep 15, 2026 SEC Short Volume: NBIX — 69.4% short (0.6M / 0.9M)
Short: 614,051 | Exempt: 0 | TRF Vol: 884,559 | Short Ratio: 69.4% | Off-exchange volume (dark pool
Insider cluster shows 2 insiders with open-market sales totaling $493K (CFO Abernethy sold 2,311 shares for $363K; anoth
CLUSTER — Impact 3/10
Sep 14, 2026 Insider
ABERNETHY MATT sold 2,311 shares
Chief Financial Officer @ $157.20 ($363.3K)
Sep 14, 2026 Insider
Boyer David W. sold 826 shares
Chief Corp. Affairs Officer @ $157.45 ($130.1K)
Sep 11, 2026 Insider
Jul 14, 2026 SEC BENEVICH ERIC surrendered for taxes 3,386 shares
Chief Commercial Officer @ $156.22 ($529.0K)
Two senior NBIX executives — Chief Legal Officer Darin Lippoldt and Chief Regulatory Officer Ingrid Delaet — exercised a
CLUSTER — Impact 3/10
Neurocrine Biosciences announced the schedule for its Q2 2026 earnings release and conference call on July 30, 2026, wit
PRESS-RELEASE — Impact 2/10
Jun 30, 2026 Inst.
NORGES BANK — NEW
973,880 shares ($164.1M)
Analyst ratings buy % -3.4%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
86% rate it Buy or better · 36 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 29, 2026 | UBS | MAINTAIN | Buy | 55% |
| Sep 11, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | 55% |
| Sep 8, 2026 | RBC Capital | REITERATE | Outperform | 55% |
| Sep 3, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Aug 13, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | 55% |
| Aug 3, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Aug 3, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Aug 3, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| Jul 31, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Jul 31, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 14 | 17 | 5 | 0 | 0 | 86% | |
| Aug 1, 2026 | 14 | 17 | 5 | 0 | 0 | 86% | |
| Jul 1, 2026 | 14 | 18 | 5 | 0 | 0 | 86% | |
| Jun 1, 2026 | 14 | 17 | 5 | 0 | 0 | 86% | |
| May 1, 2026 | 13 | 17 | 5 | 0 | 0 | 86% | |
| Apr 1, 2026 | 13 | 18 | 5 | 0 | 0 | 86% | |
| Mar 1, 2026 | 13 | 18 | 5 | 0 | 0 | 86% | |
| Feb 1, 2026 | 12 | 18 | 5 | 0 | 0 | 86% |
Price targets
Where 29 covering analysts think NBIX trades over the next 12 months.
$207.81 +45.1% upside Strong Buy
Current$143.18 Low$164.00 Median$214.00 High$253.00 29 analysts
$164.00$253.00
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
17 SEC filing reports analyzed · 2 bullish, 1 bearish, 0 mixed, 14 neutral · avg impact 3.6/10.
NEUTRALCLUSTER3/10
Insider cluster shows 2 insiders with open-market sales totaling $493K (CFO Abernethy sold 2,311 sha
Sep 15, 2026
NEUTRALCLUSTER3/10
Two senior NBIX executives — Chief Legal Officer Darin Lippoldt and Chief Regulatory Officer Ingrid
Jul 14, 2026
NEUTRALPRESS-RELEASE2/10
Neurocrine Biosciences announced the schedule for its Q2 2026 earnings release and conference call o
Jul 9, 2026
NEUTRALCLUSTER3/10
A cluster of insider selling at Neurocrine Biosciences over the past week totals $4.53M in open-mark
Jun 9, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
Clinical Trial
A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH
Phase Phase 3 — COMPLETED
Oct 2, 2026
Clinical Trial
Extension Study for Patients Entered Into Study Infacort 003
Phase Phase 3 — COMPLETED
Oct 2, 2026
Clinical Trial
Treatment of Adrenal Insufficiency in Children
Phase Phase 3 — COMPLETED
Oct 2, 2026
Clinical Trial
Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
Phase Phase 3 — COMPLETED
Oct 2, 2026
Clinical Trial
Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia
Phase Phase 3 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.74 | $2.07–$3.39 | 26.2% | +0.7% | 2↑ 1↓ | $1.0B | 16 |
| Next Q | $2.84 | $2.13–$3.65 | 51.1% | +0.9% | 2↑ 1↓ | $1.1B | 16 |
| Current FY | $10.23 | $8.98–$11.35 | 60.1% | +0.4% | 2↑ 1↓ | $3.9B | 16 |
| Next FY | $11.88 | $8.37–$17.67 | 16.1% | -0.6% | 1↑ 2↓ | $4.5B | 16 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.739 | — |
| 7d ago | $2.720 | +0.019 |
| 30d ago | $2.720 | +0.019 |
| 60d ago | $2.713 | +0.026 |
| 90d ago | $3.236 | -0.497 |
Institutional ownership
Which big funds own NBIX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $12.7B total value (75,594,335 shares) as of 2026-Q2. Top holders: BlackRock,, JPMORGAN, DODGE. Net buying activity: 41 institutions added/increased vs 9 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 13,711,607 | $2.3B | 18.1% | — |
| JPMORGAN CHASE & CO | 6,398,674 | $1.1B | 8.5% | — |
| DODGE & COX | 5,584,707 | $941.2M | 7.4% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,974,083 | $838.3M | 6.6% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,545,339 | $766.0M | 6.0% | — |
| STATE STREET CORP | 4,385,598 | $739.1M | 5.8% | — |
| AQR CAPITAL MANAGEMENT LLC | 3,818,037 | $643.5M | 5.1% | — |
| RENAISSANCE TECHNOLOGIES LLC | 2,335,897 | $393.7M | 3.1% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,138,777 | $359.6M | 2.8% | — |
| TWO SIGMA INVESTMENTS, LP | 2,076,260 | $349.9M | 2.7% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 973,880 | — | $164.1M |
| JACOBS LEVY EQUITY MANAGEMENT, INC | ADD | 520,269 | 726,112 | +39.6% | $122.4M |
| GOLDMAN SACHS GROUP INC | ADD | 349,179 | 631,892 | +81.0% | $106.5M |
| Man Group plc | ADD | 415,909 | 601,019 | +44.5% | $101.3M |
| ROYAL BANK OF CANADA | ADD | 332,300 | 583,476 | +75.6% | $98.3M |
| UBS Group AG | TRIM | 1,221,036 | 545,937 | -55.3% | $92.0M |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | DOUBLED | 93,622 | 539,961 | +476.7% | $91.0M |
| Pictet Asset Management Holding SA | TRIM | 602,643 | 430,635 | -28.5% | $72.8M |
| Rockefeller Capital Management L.P. | ADD | 282,097 | 373,548 | +32.4% | $63.0M |
| Fiera Capital Corp | TRIM | 651,255 | 373,192 | -42.7% | $62.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net -$9.2M — $0.00 bought, $9.2M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | ABERNETHY MATT | Chief Financial Officer | SELL | 2,311 | $157.20 | $363.3K |
| Sep 14, 2026 | Boyer David W. | Chief Corp. Affairs Officer | SELL | 826 | $157.45 | $130.1K |
| Sep 11, 2026 | BENEVICH ERIC | Chief Commercial Officer | TAX W/H | 3,386 | $156.22 | $529.0K |
| Sep 11, 2026 | Delaet Ingrid | Chief Regulatory Officer | AWARD | 4,483 | — | — |
| Sep 11, 2026 | Delaet Ingrid | Chief Regulatory Officer | TAX W/H | 2,419 | $156.22 | $377.9K |
| Sep 11, 2026 | ABERNETHY MATT | Chief Financial Officer | AWARD | 5,020 | — | — |
| Sep 11, 2026 | ABERNETHY MATT | Chief Financial Officer | TAX W/H | 2,709 | $156.22 | $423.2K |
| Sep 11, 2026 | BENEVICH ERIC | Chief Commercial Officer | AWARD | 6,275 | — | — |
| Sep 11, 2026 | Cooke Julie | Chief Human Resources Officer | AWARD | 3,587 | — | — |
| Sep 11, 2026 | Gano Kyle | Chief Executive Officer | TAX W/H | 994 | $156.22 | $155.3K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for NBIX.
Shares short
4,964,907
Settlement Sep 15, 2026
Change vs prior
-1.8%
Semi-monthly cycle
Days to cover
5.4
At avg daily volume
Of shares outstanding
≈4.9%
Estimate — not % of float
All NBIX filing & press-release reports (17)
- CLUSTER reportSep 15, 2026
- CLUSTER reportJul 14, 2026
- PRESS-RELEASE reportJul 9, 2026
- CLUSTER reportJun 9, 2026
- CLUSTER reportJun 9, 2026
- CLUSTER reportJun 8, 2026
- CLUSTER reportJun 4, 2026
- CLUSTER reportJun 4, 2026
- CLUSTER reportJun 2, 2026
- CLUSTER reportJun 2, 2026
- CLUSTER reportMay 29, 2026
- CLUSTER reportMay 28, 2026
- CLUSTER reportMay 21, 2026
- CLUSTER reportMay 21, 2026
- CLUSTER reportMay 18, 2026
- 8-K reportMay 18, 2026
- 8-K reportApr 6, 2026